

Advanced Enzyme Technologies Ltd.

CIN: L24200MH1989PLC051018

Sun Magnetica, 'A' wing, 5th Floor, LIC Service Road, Louiswadi, Thane (W)-400 604, India

Tel: +91-22-4170 3200, Fax: +91-22-2583 5159

Email: info@advancedenzymes.com, www.advancedenzymes.com

August 12, 2023

BSE Limited
P. J. Towers,
Dalal Street,
Mumbai- 400 001

National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1,
G Block, Bandra-Kurla Complex,
Bandra (E) Mumbai- 400 051

Scrip Code-540025

Trading Symbol-ADVENZYMES

Dear Sir,

Subject: Outcome of Board Meeting held on August 12, 2023

Ref: ISIN: INE837H01020

With reference to the notice of Board Meeting dated August 04, 2023, we hereby inform that the Board of Directors at its Meeting held on August 12, 2023 (commenced at 10.05 a.m. and concluded at 10.45 a.m.) has *inter alia*, approved the Un-audited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2023.

In view of the aforesaid, we are enclosing the following:

- Annexure I - Unaudited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2023 along with the Limited Review report issued by MSKA & Associates, Statutory Auditors of the Company as an Annexure.

The aforesaid financial results and other documents are also being uploaded on the website of the Company i.e. www.advancedenzymes.com

This is for your information and for public at large.

Thanking you,
Yours faithfully,

For Advanced Enzyme Technologies Limited



Sanjay Basantani
Company Secretary and Head – Legal

Encl.: As above



Independent Auditor's Review Report on unaudited consolidated financial results for the quarter financial results of Advance Enzyme Technologies Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To The Board of Directors Advance Enzyme Technologies Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Advance Enzyme Technologies Limited ('the Holding Company'), its subsidiaries, (the Holding Company and its subsidiaries together referred to as the 'Group') for the quarter ended 30 June 2023 ('the Statement'), being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. This Statement includes the results of the Holding Company and the following entities:

Sr. No	Name of the Entity	Relationship with the Holding Company
1	Advanced Bio-Agro Tech Limited	Subsidiary
2	Advanced Enzytech Solutions Limited	Wholly owned subsidiary
3	Advanced Enzymes USA, Inc. ('AEU')	Wholly owned subsidiary
4	Advanced Supplementary Technologies Corporation	Wholly owned subsidiary of AEU



MSKA & Associates

Chartered Accountants

5	Cal India Foods International ('CAL')	Wholly owned subsidiary of AEU
6	Enzyme Innovation, Inc	Wholly owned subsidiary of CAL
7	JC Biotech Private Limited	Subsidiary
8	Scitech Specialities Private Limited	Subsidiary
9	Advanced Enzymes (Malaysia) Sdn. Bhd	Wholly owned subsidiary
10	Advanced Enzymes Europe B.V. ('AEEBV')	Wholly owned subsidiary
11	Evoxx Technologies GmbH	Wholly owned subsidiary of AEEBV
12	Saiganesh Enzytech Solutions Private Limited	Subsidiary (with effect from January 3, 2023)

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 to 8 below, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial results of five subsidiaries included in the Statement, whose interim financial results reflects total revenues of Rs. 478.63 millions, total net profit after tax of Rs. 3.33 millions and total comprehensive income of Rs.3.08 millions, for the quarter ended 30 June 2023 as considered in the Statement. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the report of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of the above matter.

7. One subsidiary is located outside India whose interim financial result has been prepared in accordance with the accounting principles generally accepted in their respective country and which has been reviewed by other auditor under generally accepted auditing standards applicable in their respective country. The Holding Company's Management has converted the interim financial results of such subsidiary located outside India from accounting principles generally accepted in their respective country to accounting principles generally accepted in India.

We have reviewed these conversion adjustments made by the Holding Company's Management. Our conclusion on the Statement, in so far as it relates to the interim financial results of such subsidiary located outside India is based on the report of other auditor and the conversion adjustments prepared by the Management of the Holding Company and reviewed by us.

Our conclusion is not modified in respect of the above matter.



MSKA & Associates

Chartered Accountants

8. The Statement includes the interim financial results of three subsidiaries which have not been reviewed by their auditors, whose interim financial results reflects total revenue of Rs. 36.20 millions, total net (loss) after tax of Rs. (3.15) millions and total comprehensive (loss) of Rs. (3.13) millions for the quarter ended 30 June 2023 as considered in the Statement. These interim financial results have been furnished to us by the Management and our conclusion on the Statement in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on such management prepared unaudited interim financial results. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Our conclusion is not modified in respect of the above matter.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No.105047W

Amrith Vaidya
Partner

Membership No.: 101739

UDIN: 23101739B6XTW8547



Place: Mumbai
Date: 12 August 2023

Advanced Enzyme Technologies Limited
CIN No.: L24200MH1989PLC051018

Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India.

Tel No:91-22-41703220 Fax No: +91-22-25835159

Website: www.advancedenzymes.com, Email Id :sanjay@advancedenzymes.com

Statement of unaudited consolidated financial results for the quarter ended 30 June 2023

(₹ in million except per share data)

Particulars	Quarter ended			
	30-Jun-23 Unaudited	31-Mar-23 Audited (Refer Note [x])	30-Jun-22 Unaudited	Year ended 31-Mar-23 Audited
1 Revenue from operations	1,472.76	1,387.10	1,211.22	5,406.37
2 Other Income	66.74	110.78	19.94	254.57
3 Total Income (1+2)	1,539.50	1,497.88	1,231.16	5,660.94
4 Expenses				
(a) Cost of materials consumed	456.79	355.13	241.20	1275.12
(b) Purchases of stock-in-trade #	0.00	0.15	-	0.17
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(86.85)	(19.59)	30.54	42.75
(d) Employee benefits expense	320.83	299.62	281.11	1148.04
(e) Finance costs (including exchange difference)	6.49	6.12	5.84	24.21
(f) Depreciation and amortisation expense	86.34	84.49	86.42	350.29
(g) Other expenses	341.84	310.32	349.08	1375.86
Total Expenses	1,125.44	1,036.24	994.19	4,216.44
5 Profit before exceptional item and tax (3-4)	414.06	461.64	236.97	1,444.50
6 Exceptional item (refer note ix)	-	40.62	-	40.62
7 Profit before tax (5-6)	414.06	421.02	236.97	1,403.88
8 Tax expense				
Current tax	125.68	120.52	68.84	428.61
Deferred tax charge / (credit)	(5.41)	(20.65)	(7.68)	(63.39)
Total tax expense	120.27	99.87	61.16	365.22
9 Net profit for the period (7-8)	293.79	321.15	175.81	1,038.66
10 Other comprehensive income				
A (i) Items that will not be reclassified to profit or loss				
Remeasurements of defined benefit liability/(asset)	(0.36)	9.31	(0.14)	7.85
(ii) Income tax related to items that will not be reclassified to profit or loss	0.10	(2.35)	0.05	(1.94)
B (i) Items that will be reclassified to profit or loss				
Exchange differences in translating financial statements of foreign operations	(20.14)	(37.84)	231.30	540.38
(ii) Income tax related to items that will be reclassified to profit or loss	-	-	-	-
Total Other comprehensive income	(20.40)	(30.88)	231.21	546.29
11 Total comprehensive income (9+10)	273.39	290.27	407.02	1,584.95
12 Net profit attributable to:				
Shareholders of the Company	288.10	321.23	178.73	1,056.39
Non-controlling interest	5.69	(0.08)	(2.92)	(17.73)
13 Other comprehensive income attributable to:				
Shareholders of the Company	(20.37)	(31.68)	231.17	545.60
Non-controlling interest	(0.03)	0.80	0.04	0.69
14 Total comprehensive income attributable to:				
Shareholders of the Company	267.73	289.55	409.90	1,601.98
Non-controlling interest	5.66	0.72	(2.88)	(17.03)
15 Paid-up Equity Share Capital (Face Value ₹ 2 each fully paid up)	223.65	223.65	223.61	223.65
16 Other equity				12,127.04
17 Earnings Per Share of ₹ 2 each (not annualized)				
(a) ₹ (Basic)	2.58	2.87	1.60	9.45
(b) ₹ (Diluted)	2.58	2.87	1.60	9.45

Figures are below Rs 0.01 Million, hence disclosed as Rs 0.00



Handwritten signature/initials

Advanced Enzyme Technologies Limited

CIN No.: L24200MH1989PLC051018

Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India.

Tel No:91-22-41703220 Fax No: +91-22-25835159

Website: www.advancedenzymes.com, Email Id :sanjay@advancedenzymes.com

Notes:

(i) The above unaudited consolidated financial results include the financial results of Advanced Enzyme Technologies Limited (the "Company" or the "Holding Company") and the financial results of the subsidiary companies, Advanced Bio-Agro Tech Limited (India), Advanced Enzytech Solutions Limited (India), JC Biotech Private Limited (India), Scitech Specialities Private Limited (India), Saiganesh Enzytech Solutions Private Limited (India) (w.e.f. 03 January 2023), Advanced Enzymes USA, Inc. (U.S.A.), Cal India Foods International (U.S.A.), Advanced Supplementary Technologies Corporation (U.S.A.), Enzyme Innovation, Inc. (U.S.A.), Dynamic Enzymes, Inc. (U.S.A.) (up to 31 March 2023), Advanced Enzymes (Malaysia) Sdn. Bhd. (Malaysia), Advanced Enzymes Europe B.V. (Netherlands) and Evoox Technologies GmbH (Germany). The Holding Company and its subsidiary companies constitute the "Group".

(ii) The above unaudited consolidated financial results of the Group were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on 12 August 2023. The above results have been subjected to 'limited review' by the statutory auditors of the Company and they have expressed an unmodified opinion. The limited review report will be filed with stock exchanges and will be available on the Company's website. The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.

(iii) On 03 January 2023, the Company had acquired additional stake of 4.83% in its subsidiary JC Biotech Private Limited for consideration of Rs 68.00 million. Post this additional acquisition the Company holds 89.83% stake in the subsidiary. On account of acquisition of additional stake of 4.83% by the Company in JC Biotech Private Limited, Non-controlling interest was reduced by Rs. 41.17 million and Rs. 26.83 million was adjusted in other equity. Impact of additional stake of 4.83% acquired in subsidiary JC Biotech Private Limited as on the date of acquisition of the additional stake is summarised as below:-

Particulars	₹ in million
(A) Consideration paid to acquire additional 4.83% stake	68.00
(B) Value of 4.83% non-controlling interest acquired	41.16
(C) Adjusted in other equity (A-B)	26.84

(iv) On 03 January 2023, the Group completed the acquisition of 50% of the paid up equity share capital by subscription of 19,991,663 equity shares in Saiganesh Enzytech Solutions Private Limited ('SESPL') having face value of Rs. 1 per share for a total consideration of Rs 59.97 million. SESPL is primarily engaged into extracting Latex from papaya, purifying and providing finish papain enzyme in liquid form (agriculture extraction of Papain enzyme). As of 31 March 2023, the Group has accounted for the acquisition and finalised the purchase price allocation. The Group on finalising of purchase price allocation has recognised fair value of Net Assets acquired of Rs. 32.52 million resulting in Goodwill of Rs. 15.10 million. The figures for the three months and year ended 31 March 2023, which includes figures for SESPL from the period 03 January 2023 to 31 March 2023, are not comparable with the previous corresponding periods.

(v) On 01 April 2023, the Group completed the acquisition of Shri Ganesh Industrial Enzymes (a partnership firm based in Burhanpur, Madhya Pradesh) ("SGIE"), through a slump sale for a total consideration of Rs. 9.00 million. The Group on finalising of purchase price allocation has recognised fair value of Net Assets acquired of Rs. 5.71 million resulting in Goodwill of Rs. 3.29 million.

(vi) The Group operates only in one business segment viz. 'manufacturing and sales of enzymes'.

(vii) The Company has allotted 2,000 equity shares during the quarter ended 31 March 2023 and 23,400 equity shares during the year ended 31 March 2023 to employees under the 'AETL Employee Stock Option Scheme 2015' ("AETL ESOS 2015").

(viii) The Shareholders at its Annual General meeting held on 19 August 2022 approved the Employee Stock Option Scheme 2022 ("ESOP Scheme 2022") of the Company and its extension to the subsidiaries of the Company. National Stock Exchange of India Limited and BSE Limited (Stock Exchanges) vide their letter/e-letter dated 06 October 2022 and 18 October 2022 respectively granted its 'In-Principle' approval for listing of 25,00,000 Equity Shares of Rs. 2 each which may arise out of exercise of Options as and when exercised from time to time subject to the prescribed conditions. The Company has not yet granted any Options under the ESOP Scheme 2022.

(ix) On 24 January 2023, a fire occurred in one of facility Scitech Specialities Private Limited ("SSPL"), subsidiary of the Company, situated at Plot No A-43, STICE, Musalgaon, Sinnar, Nashik. There has been loss to assets comprising of Inventories, Buildings, Plant & Machinery and other Fixed Assets etc. As per the best estimate of the Management of SSPL, the book value of the loss due to fire is Rs 40.62 million, which is included in exceptional items in the statement of profit and loss. SSPL is adequately insured and in process of filing the required documents with the Insurance Company. The Insurance claim would be recognised as per the requirements of the accounting standards in the subsequent years on the admission/approval of the claim by the Insurance Company.

(x) The figures for the quarter ended 31 March 2023 are the balancing figures between consolidated audited figures in respect of the full financial year and the published year to date figures upto the end of the third quarter of the relevant financial year. Also, the figures up to the end of the third quarter had only been reviewed and not subjected to audit.

(xi) Effective date 07 April 2023, loan given by the Company to Advanced Enzymes Europe B.V. (AEEBV) including the outstanding interest aggregating to Rs 329 million got converted into 2,276,837 fully paid up equity shares. The value per equity share is EUR 1.63 and the face value of EUR 1 per share. Pursuant to this conversion, the Company now holds 4,276,837 equity share of AEEBV and the Company continues to be 100% shareholder of AEEBV.

(xii) Effective date 01 April 2023, Advanced Supplementary Technologies Corporation (U.S.A.) and Dynamic Enzymes, Inc. (U.S.A.) wholly owned subsidiaries of Advanced Enzymes USA, Inc. (U.S.A.) merged. As a result of merger, Dynamic Enzymes, Inc. (U.S.A.) has been merged with Advanced Supplementary Technologies Corporation (U.S.A.) and Dynamic Enzymes, Inc. (U.S.A.) has ceased to exist.

(xiii) The Board of Directors of the Company declared and paid interim dividend of Rs. 4/- per equity share during the quarter.

(xiv) The Board of Directors of the Company in its meeting held on 13 May 2023 have proposed the final dividend for the financial year 2022-23 of Rs 1/- per equity share and the same will be paid after approval of the shareholders in Annual General Meeting of the Company.

(xv) Previous period/ year amounts have been regrouped/ reclassified wherever necessary.



By Order of the Board of Directors
For Advanced Enzyme Technologies Limited
CIN No.: L24200MH1989PLC051018

M.M. Kabra

M.M. Kabra
Wholtime Director
DIN : 00148294



Independent Auditor's Review Report on unaudited Standalone financial results for the quarter of Advanced Enzyme Technologies Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To The Board of Directors of Advanced Enzyme Technologies Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Advanced Enzyme Technologies Limited ('the Company') for the quarter ended 30 June 2023 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No.105047W



Amrish Vaidya
Partner

Membership No.: 101739

UDIN: 23101739B6XTWT5360



Place: Mumbai

Date: 12 August 2023

Advanced Enzyme Technologies Limited

CIN No.: L24200MH1989PLC051018

Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India.

Tel No:91-22-41703220 Fax No: +91-22-25835159

Website: www.advancedenzymes.com, Email Id :sanjay@advancedenzymes.com

Statement of Unaudited standalone financial results for the quarter ended 30 June 2023

		(₹ in Million except per share data)			
	Particulars	Quarter ended			Year ended
		30-Jun-23 Unaudited	31-Mar-23 Audited (Refer note vii)	30-Jun-22 Unaudited	31-Mar-23 Audited
1	Revenue from operations	853.49	825.60	721.10	3,115.29
2	Other Income	512.49	28.10	12.45	98.08
3	Total Income (1+2)	1,365.98	853.70	733.55	3,213.37
4	Expenses				
	(a) Cost of materials consumed	352.88	307.09	301.25	1,214.26
	(b) Purchases of stock-in-trade	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(60.88)	(15.46)	30.88	14.80
	(d) Employee benefits expense	120.19	108.48	106.53	414.20
	(e) Finance costs (including exchange difference)	0.35	0.57	0.28	1.35
	(f) Depreciation and amortisation expense	25.07	27.57	24.09	102.83
	(g) Other expenses	193.53	192.67	167.76	723.15
	Total expenses	631.14	620.92	630.79	2,470.59
5	Profit before exceptional item and tax (3-4)	734.84	232.78	102.76	742.78
6	Exceptional item	-	-	-	-
7	Profit before tax (5-6)	734.84	232.78	102.76	742.78
8	Tax expense				
	Current tax	60.65	52.29	26.06	182.54
	Deferred tax charge/(credit)	(0.68)	5.52	(1.08)	4.97
	Total tax expense	59.97	57.81	24.98	187.51
9	Net profit for the period (7-8)	674.87	174.97	77.78	555.27
10	Other comprehensive income				
	A (i) Items that will not be reclassified to Profit or Loss				
	Remeasurements of defined benefit liability/(asset)	-	6.59	-	6.59
	(ii) Income tax related to items that will not be reclassified to Profit or Loss	-	(1.66)	-	(1.66)
	B (i) Items that will be reclassified to Profit or Loss	-	-	-	-
	(ii) Income tax related to items that will be reclassified to Profit or Loss	-	-	-	-
	Total Other comprehensive income	-	4.93	-	4.93
11	Total comprehensive income (9+10)	674.87	179.90	77.78	560.20
12	Paid-up Equity Share Capital (Face Value ₹ 2 each fully paid up)	223.65	223.65	223.61	223.65
13	Other equity				5,029.67
14	Earnings Per Share of ₹ 2 each (not annualized)				
	(a) ₹ (Basic)	6.04	1.56	0.70	4.97
	(b) ₹ (Diluted)	6.04	1.56	0.70	4.97



Advanced Enzyme Technologies Limited

CIN No.: L24200MH1989PLC051018

Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India.

Tel No:91-22-41703220 Fax No: +91-22-25835159

Website: www.advancedenzymes.com, Email Id :sanjay@advancedenzymes.com

Notes:

(i) The above standalone financial results of the Advanced Enzyme Technologies Limited ('the Company') were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on 12 August 2023. The above results have been subjected to 'Limited review' by the statutory auditors of the Company and they have expressed an unmodified opinion. The limited review report will be filed with stock exchanges and will be available on the Company's website. The above results has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies in India.

(ii) The Company operates only in one business segment viz. 'manufacturing and sales of enzymes'.

(iii) The Company has allotted 2,000 equity shares during the quarter ended 31 March 2023 and 23,400 equity shares during the year ended 31 March 2023 to employees under the 'AETL Employee Stock Option Scheme 2015' - ('AETL ESOS 2015').

(iv) "The Shareholders at its Annual General meeting held on 19 August 2022 approved the Employee Stock Option Scheme 2022 ("ESOP Scheme 2022") of the Company and its extension to the subsidiaries of the Company. National Stock Exchange of India Limited and BSE Limited (Stock Exchanges) vide their letter/e-letter dated 06 October 2022 and 18 October 2022 respectively granted its 'In-Principle' approval for listing of 2,500,000 Equity Shares of Rs. 2 each which may arise out of exercise of Options as and when exercised from time to time subject to the prescribed conditions. The Company has not yet granted any Options under the ESOP Scheme 2022."

(v) On 3 January 2023, the Company has acquired additional stake of 4.83% in its subsidiary JC Biotech Private Limited for a consideration of Rs 68.00 million. Post this additional acquisition the Company holds 89.83% stake in the subsidiary.

(vi) On 3 January 2023, the Company completed the acquisition of 50% of the paid up equity share capital by subscription of 19,991,663 equity shares in Saiganesh Enzytech Solutions Private Limited ('SESPL') having face value of Rs 1 per share for a total consideration of Rs 59.97 million. SESPL is primarily engaged into extracting Latex from papaya, purifying and providing finish papain enzyme in liquid form (agriculture extraction of Papain enzyme)

(vii) The figures for the quarter ended 31 March 2023 are the balancing figures between standalone audited figures in respect of the full financial year and the published year to date figures upto the end of the third quarter of the relevant financial year. Also, the figures up to the end of the third quarter had only been reviewed and not subjected to audit.

(viii) The Board of Directors of the Company declared and paid interim dividend of Rs 4/- per equity share during the current quarter.

(ix) The Board of Directors in its meeting held on 13 May 2023 have proposed the final dividend for the financial year 2022-23 of Rs 1 per equity share and the same will be paid after approval of the shareholders in Annual General Meeting of the Company.

(x) Previous year / period amounts have been regrouped / reclassified wherever necessary.



Place: Nashik
Dated: 12 August 2023

By Order of the Board of Directors
For Advanced Enzyme Technologies Limited
CIN: L24200MH1989PLC051018

M. M. Kabra
M. M. Kabra
Wholesale Director
DIN : 00148294

